Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies.
We believe the success of our colleagues drives the success of our mission. We are committed to creating a company passionate about equality, inclusion, and respect. When everyone feels supported and encouraged to give their best, we will collectively deliver outstanding results.
We are seeking an experienced Vice President, Translational Biology, reporting to the CSO, with a background in Immunology and Clinical Biomarker Science for immunotherapies for cancer and infectious diseases to join our team.
You will oversee VIR’s Translational Biology department, including leading an established team of translational and clinical biomarker scientists, overseeing clinical biomarker strategy and execution across all stages of development. You will lead a multidisciplinary team of scientists and operational experts across, providing strategic direction, mentorship, and support to foster a culture of collaboration, innovation, and excellence. You will work closely with Research, Clinical Development, Regulatory Affairs, and Program Teams to ensure seamless integration of translational activities into clinical trial protocols that are needed to address key biological questions about mechanism of action, identify patient populations most likely to benefit, evaluate therapeutic combinations, and generate novel biomarkers of response, and to ensure program execution.
The role requires interaction with a broad range of stakeholders, both internal and external partners including academic research centers, CROs, CDMOs, scientific and clinical advisory board members. You will also contribute significantly to our research and clinical development efforts as a core member of our research governance committees, and function as a core team member of our CSO Leadership Team and CSO Strategy Team to provide scientific input for translational and clinical biomarker strategy of all our pipelines.
This role is located in our San Francisco headquarters with an expectation of 4 days per week in office.
WHAT YOU'LL DO
- Leadership: Provide strategic leadership for the Translational Biology Group (translational scientists with expertise in virology, immunology, oncology, and biomarker development. and promote a culture of collaboration, innovation, and excellence.
- Strategy: Develop overarching translational strategies across programs to support the pre-clinical and clinical development of infectious disease and immunotherapy product candidates, ensuring alignment with corporate goals.
- Execution: Work closely with cross-functional teams to design and execute biomarker-driven clinical trials. Lead teams in the development and validation of biomarker assays for clinical use, including proficiency testing, analytical validation, and clinical validation. Analyze biomarker data and generate reports to support clinical decision-making. Participate in the preparation of regulatory submissions related to biomarkers for infectious disease and immunotherapy programs.
- Stakeholder and Risk Management: Represent translational biology internally, externally, and with regulatory authorities. Oversee and manage team who partner with external collaborations such as academic institutions, contract research organizations, and other partners in the field of biomarker discovery and translational biology. Provide updates to senior leadership on status of biomarker activities/strategies, identify potential risks and challenges related to clinical translational activities, and develop mitigation strategies to ensure successful execution of clinical programs.
- Scientific expertise/innovation: Stay abreast of the latest developments in immunology, translational medicine, and regulatory landscape, incorporating relevant insights into program strategies. Establish new and innovative assays and methods for assessing biomarker discovery to further our understanding of our therapeutics in the clinic.
- Budgeting: Ensure financial resources are effectively allocated and managed to support achievement of the priority objectives for translational biology group.
- Ph.D. or equivalent advanced degree in a relevant scientific discipline (immunology background preferred) with 15+ years of experience in the pharmaceutical/biotechnology industry, with a focus on biomarker science for infectious disease and immune-therapies as for oncology.
- Technical expertise in immunology, biomarker discovery and development in clinical trials, including assay development, validation, and data analysis. Demonstrated experience in leading clinical biomarker development for innovative early clinical development, particularly in immunotherapy.
- Experience in bringing drug candidates from pre-IND through PI/II and, ideally, to BLA/NDA.
- History of building relationships and promoting engagement across all partners, including the senior management, scientific and clinical advisory boards, academic and biopharma partners, and CROs.
- Sound business acumen with a pragmatic, results-oriented leadership style that can translate innovation, creative strategies, and conceptual thinking into plans.
- Prior experience leading large teams and management skills to inspire and develop individuals.
- Strong communication and presentation skills with the ability to generate scientific reports and presentations.
- Demonstrated ability to work in a fast-paced, dynamic environment.
- This role is located in San Francisco at our corporate office
#LI-225024411_AA1
#LI-Onsite
The expected salary range for this position is $290,000 to $340,000. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors.
Vir’s compensation and benefits are aligned with the current market and commensurate with the person’s experience and qualifications. All full-time employees receive a package that includes: compensation, bonus and equity as well as many other Vir benefits and perks such as: health, dental, vision, life and disability insurance benefits, non-accrual paid time off, company shut down for holidays, commuter benefits, child care reimbursement, education reimbursement, 401K match and lunch for all onsite employees!
Applicants must currently be authorized to work for any employer in the U.S. We are unable to sponsor or take over sponsorship of an employment Visa at this time.
Vir Biotechnology (“Vir”) is an equal opportunity employer. All employment decisions at Vir are based on legitimate, non-discriminatory business requirements, job duties and individual qualifications. Employment decisions are made without regard to race, color, religion, sex (including pregnancy), gender, gender identity, gender expression, sexual orientation, age, parental status, marital status, national origin, ancestry, disability, medical condition, genetic information (including family medical history), political affiliation, military service or any other legally protected characteristic.
This commitment extends to all management practices and decisions, including recruitment and hiring, compensation, appraisal systems, promotions, training and career development programs. Vir also strongly commits to providing employees with a work environment free of unlawful discrimination or harassment.
Vir Human Resources leads recruitment and employment for Vir. Unsolicited resumes sent to Vir from recruiters do not constitute any type of relationship between the recruiter and Vir and do not obligate Vir to pay fees should we hire from those resumes. We ask that external recruiters and/or agencies not contact or present candidates directly to our hiring manager or employees.
For hires based in the United States, Vir Biotechnology, Inc., participates in E-Verify.
Candidate Privacy Notice
Top Skills
What We Do
Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden.
Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm
We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world.
We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™.
Join us as we pursue our mission to transform lives.
It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
